PL366911A1 - Dopłucne podawanie chemicznie modyfikowanej insuliny - Google Patents
Dopłucne podawanie chemicznie modyfikowanej insulinyInfo
- Publication number
- PL366911A1 PL366911A1 PL02366911A PL36691102A PL366911A1 PL 366911 A1 PL366911 A1 PL 366911A1 PL 02366911 A PL02366911 A PL 02366911A PL 36691102 A PL36691102 A PL 36691102A PL 366911 A1 PL366911 A1 PL 366911A1
- Authority
- PL
- Poland
- Prior art keywords
- chemically modified
- pulmonary administration
- modified insulin
- insulin
- pulmonary
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29242301P | 2001-05-21 | 2001-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL366911A1 true PL366911A1 (pl) | 2005-02-07 |
Family
ID=23124608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02366911A PL366911A1 (pl) | 2001-05-21 | 2002-05-21 | Dopłucne podawanie chemicznie modyfikowanej insuliny |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US6838076B2 (pl) |
| EP (1) | EP1395294A4 (pl) |
| JP (1) | JP2004535401A (pl) |
| KR (1) | KR20030097876A (pl) |
| CN (2) | CN101045166A (pl) |
| AP (1) | AP1763A (pl) |
| AR (1) | AR033903A1 (pl) |
| AU (1) | AU2002303869B2 (pl) |
| BG (1) | BG108494A (pl) |
| BR (1) | BR0209896A (pl) |
| CA (1) | CA2447236A1 (pl) |
| CO (1) | CO5540371A2 (pl) |
| CZ (1) | CZ20033182A3 (pl) |
| EA (1) | EA007408B1 (pl) |
| EC (1) | ECSP034855A (pl) |
| GE (1) | GEP20063917B (pl) |
| HR (1) | HRP20030949A2 (pl) |
| HU (1) | HUP0400442A2 (pl) |
| IL (2) | IL158862A0 (pl) |
| IS (1) | IS7043A (pl) |
| LT (1) | LT5153B (pl) |
| LV (1) | LV13197B (pl) |
| MA (1) | MA26185A1 (pl) |
| MX (1) | MXPA03010649A (pl) |
| MY (1) | MY137181A (pl) |
| NO (1) | NO20035157D0 (pl) |
| NZ (1) | NZ529572A (pl) |
| OA (1) | OA13136A (pl) |
| PL (1) | PL366911A1 (pl) |
| SK (1) | SK15532003A3 (pl) |
| TN (1) | TNSN03116A1 (pl) |
| TR (1) | TR200400295T2 (pl) |
| WO (1) | WO2002094200A2 (pl) |
| YU (1) | YU98503A (pl) |
| ZA (1) | ZA200309085B (pl) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| PL366911A1 (pl) * | 2001-05-21 | 2005-02-07 | Nektar Therapeutics | Dopłucne podawanie chemicznie modyfikowanej insuliny |
| NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
| JP4959919B2 (ja) * | 2001-12-21 | 2012-06-27 | スリーエム イノベイティブ プロパティズ カンパニー | 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物 |
| ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| DE60333758D1 (de) | 2002-06-07 | 2010-09-23 | Dyax Corp | Prevention und Verringerung von Ischemia |
| SI1596887T1 (sl) * | 2003-02-26 | 2022-05-31 | Nektar Therapeutics | Konjugati polimer-del faktorja VIII |
| CN101514223B (zh) * | 2003-04-11 | 2017-03-01 | 安特里阿比奥有限公司 | 位点特异性蛋白质偶联物的制备方法 |
| EP1491554A1 (en) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| JP4739207B2 (ja) * | 2003-08-29 | 2011-08-03 | ダイアックス コーポレーション | ポリペグ化されたプロテアーゼインヒビター |
| WO2005021556A2 (en) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Modified protease inhibitors |
| GB0328629D0 (en) * | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
| JP2008505853A (ja) | 2004-04-13 | 2008-02-28 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体 |
| PL2626368T3 (pl) * | 2004-07-19 | 2017-06-30 | Biocon Limited | Koniugaty insulina-oligomer, ich formulacje i zastosowania |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| PL2322180T3 (pl) | 2004-08-23 | 2015-10-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
| US20060046852A1 (en) * | 2004-08-26 | 2006-03-02 | Rowe Richard E | Wide area gaming system |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| US8245758B2 (en) * | 2006-10-30 | 2012-08-21 | GM Global Technology Operations LLC | Coulomb damped disc brake rotor and method of manufacturing |
| WO2006076277A1 (en) * | 2005-01-10 | 2006-07-20 | Nektar Therapeutics | Compositions and methods for increasing the bioavailability of pulmonarily administered insulin |
| WO2006079641A2 (en) * | 2005-01-27 | 2006-08-03 | Novo Nordisk A/S | Insulin derivatives conjugated with structurally well defined branched polymers |
| TWI376234B (en) * | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
| EP2256130B1 (en) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| WO2006082205A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
| WO2006097521A1 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| US20060271011A1 (en) * | 2005-05-25 | 2006-11-30 | Mock Bradley D | Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced |
| CN104324366B (zh) * | 2005-09-14 | 2016-10-05 | 曼金德公司 | 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法 |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US20080210748A1 (en) * | 2005-11-30 | 2008-09-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware, | Systems and methods for receiving pathogen related information and responding |
| US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
| US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20070289258A1 (en) * | 2006-06-14 | 2007-12-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Individualized pharmaceutical selection and packaging |
| US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20080004905A1 (en) * | 2006-06-28 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for analysis of nutraceutical associated components |
| US20080114577A1 (en) * | 2005-11-30 | 2008-05-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems associated with nutraceutical related assays |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US20080052114A1 (en) * | 2005-11-30 | 2008-02-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
| US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
| US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US20070174128A1 (en) * | 2005-11-30 | 2007-07-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| US20070292404A1 (en) * | 2006-03-27 | 2007-12-20 | Biosynexus Incorporated | Antimicrobial polymer conjugates |
| US8840882B2 (en) | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| PL1873166T3 (pl) | 2006-06-30 | 2011-03-31 | Conaris Res Institute Ag | Ulepszone dimery sgp 130Fc |
| WO2008010991A2 (en) * | 2006-07-17 | 2008-01-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| EP2049149B1 (en) * | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Pegylated extended insulins |
| CA2659809A1 (en) * | 2006-08-04 | 2008-02-14 | Pharmathene Inc. | Long half-life recombinant butyrylcholinesterase |
| DK2074141T3 (en) | 2006-09-22 | 2016-11-28 | Novo Nordisk As | The protease resistant insulin analogues. |
| WO2008067158A2 (en) | 2006-11-13 | 2008-06-05 | Auxagen, Inc. | METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR |
| WO2008084051A1 (en) * | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mixtures of pegylated insulin and fast acting insulin for pulmonary administration |
| US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
| CN101686687A (zh) * | 2007-02-28 | 2010-03-31 | 塞瑞纳治疗公司 | 活化的聚噁唑啉及包含该聚噁唑啉的组合物 |
| JP5496082B2 (ja) | 2007-04-30 | 2014-05-21 | ノボ・ノルデイスク・エー／エス | タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物 |
| US8633152B2 (en) * | 2007-08-07 | 2014-01-21 | Nanomaterials Technology Pte Ltd | Process for making micro-sized protein particles |
| WO2009029656A1 (en) * | 2007-08-27 | 2009-03-05 | Auxagen, Inc. | METHODS FOR INHIBITING TGF-β |
| US8697062B2 (en) * | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
| ES2664822T3 (es) | 2007-10-16 | 2018-04-23 | Biocon Limited | Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma |
| CN101795680A (zh) * | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
| CN101970477B (zh) | 2008-03-14 | 2014-12-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定的胰岛素类似物 |
| EP2910569B1 (en) | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| US8488661B2 (en) * | 2008-06-13 | 2013-07-16 | Verizon Patent And Licensing Inc. | Systems and methods for data streaming |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| WO2010033507A1 (en) * | 2008-09-16 | 2010-03-25 | St. Louis University | Method of enhancing tgf-beta signalling |
| EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| US8029782B2 (en) | 2008-10-01 | 2011-10-04 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| JP5788806B2 (ja) | 2008-12-29 | 2015-10-07 | マンカインド コーポレイション | 薬物送達剤用置換ジケトピペラジン及びその塩、これらを含む治療用組成物、微粒子組成物及び乾燥粉末組成物、並びに、その調整方法 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CN102307594A (zh) | 2009-01-06 | 2012-01-04 | 戴埃克斯有限公司 | 用激肽释放酶抑制剂治疗粘膜炎 |
| DK2405963T3 (da) | 2009-03-11 | 2013-12-16 | Mannkind Corp | Apparat, system og fremgangsmåde til at måle modstand i en inhalator |
| KR20180079458A (ko) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| AU2010277560B2 (en) * | 2009-07-31 | 2014-12-11 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
| CN102548583B (zh) | 2009-07-31 | 2015-04-22 | 赛诺菲-安万特德国有限公司 | 包含胰岛素连接物缀合物的前药 |
| EP2488172A4 (en) | 2009-10-13 | 2014-08-13 | Univ Michigan | DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS |
| US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| US8729245B2 (en) | 2009-12-21 | 2014-05-20 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
| EP4011917A1 (en) | 2010-01-06 | 2022-06-15 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
| BR112012033060A2 (pt) | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| US8816055B2 (en) | 2011-01-06 | 2014-08-26 | Dyax Corp. | Plasma kallikrein binding proteins |
| US9187547B2 (en) | 2011-03-15 | 2015-11-17 | Novo Nordisk A/S | Human insulin analogues and derivatives comprising cysteine substitutions |
| CN102675452B (zh) | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
| AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
| CN102504022A (zh) * | 2011-11-30 | 2012-06-20 | 苏州元基生物技术有限公司 | 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法 |
| BR112014025132A2 (pt) | 2012-04-11 | 2017-07-11 | Novo Nordisk As | formulações de insulina |
| US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
| SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体 |
| AU2014228415B2 (en) | 2013-03-15 | 2018-08-09 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| KR102465025B1 (ko) | 2013-07-18 | 2022-11-09 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| CA2924109A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| CA2926701A1 (en) | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| WO2015095406A1 (en) | 2013-12-18 | 2015-06-25 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| HUE066987T2 (hu) | 2014-12-01 | 2024-09-28 | Ferring Bv | Szelektív il-6-transz-szignalizációt gátló szert tartalmazó készítmények |
| PL3226888T3 (pl) | 2014-12-01 | 2021-11-02 | Ferring B.V. | Podawanie selektywnego transsygnałowego inhibitora IL-6 |
| EA201891388A1 (ru) | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека |
| WO2017180708A1 (en) | 2016-04-12 | 2017-10-19 | Cell and Molecular Tissue Engineering, LLC | Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site |
| CN109952116B (zh) * | 2016-11-02 | 2021-02-09 | 陶氏环球技术有限责任公司 | 固体非水性凝胶空气增香剂 |
| SI3554534T1 (sl) | 2016-12-16 | 2021-09-30 | Novo Nordisk A/S | Farmacevtski sestavki, ki vsebujejo inzulin |
| CN117794946A (zh) | 2021-06-09 | 2024-03-29 | 斯克利普斯研究所 | 长效双重gip/glp-1肽缀合物及使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4652548A (en) | 1981-08-27 | 1987-03-24 | Eli Lilly And Company | Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin |
| DOP1982004086A (es) | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
| US4654324A (en) | 1981-08-27 | 1987-03-31 | Eli Lilly And Company | Human proinsulin pharmaceutical formulations |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| EP0400472B1 (en) | 1989-05-27 | 1996-04-03 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| AU2455295A (en) * | 1994-05-20 | 1995-12-18 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, process for producing the same, and intermediate compound tehrefor |
| US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE19628143A1 (de) | 1996-07-12 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| HUP0004096A3 (en) | 1997-10-24 | 2001-12-28 | Novo Nordisk As | Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| DE69925276T2 (de) | 1998-07-27 | 2005-10-06 | Emisphere Technologies, Inc. | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen |
| WO2000033866A1 (en) * | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
| IL143962A0 (en) | 1999-01-08 | 2002-04-21 | Emisphere Tech Inc | Polymeric delivery agents and delivery agent compounds |
| US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| US6323311B1 (en) * | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| WO2001068141A2 (en) | 2000-03-17 | 2001-09-20 | Maxygen Aps | Dispersions of polypeptide conjugates |
| WO2002092147A2 (en) | 2001-05-11 | 2002-11-21 | Aradigm Corporation | Optimization of the molecular properties and formulation of proteins delivered by inhalation |
| PL366911A1 (pl) * | 2001-05-21 | 2005-02-07 | Nektar Therapeutics | Dopłucne podawanie chemicznie modyfikowanej insuliny |
| US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| PT1418890E (pt) * | 2001-08-16 | 2008-06-09 | Baxter Int | Formulações de micropartículas à base de propulsor |
-
2002
- 2002-05-21 PL PL02366911A patent/PL366911A1/pl not_active Application Discontinuation
- 2002-05-21 MX MXPA03010649A patent/MXPA03010649A/es active IP Right Grant
- 2002-05-21 US US10/154,057 patent/US6838076B2/en not_active Expired - Lifetime
- 2002-05-21 SK SK1553-2003A patent/SK15532003A3/sk not_active Application Discontinuation
- 2002-05-21 OA OA1200300305A patent/OA13136A/en unknown
- 2002-05-21 AP APAP/P/2003/002918A patent/AP1763A/en active
- 2002-05-21 CA CA002447236A patent/CA2447236A1/en not_active Abandoned
- 2002-05-21 WO PCT/US2002/016464 patent/WO2002094200A2/en active IP Right Grant
- 2002-05-21 CN CNA2007100855527A patent/CN101045166A/zh active Pending
- 2002-05-21 GE GE5398A patent/GEP20063917B/en unknown
- 2002-05-21 JP JP2002590921A patent/JP2004535401A/ja active Pending
- 2002-05-21 CZ CZ20033182A patent/CZ20033182A3/cs unknown
- 2002-05-21 KR KR10-2003-7014954A patent/KR20030097876A/ko not_active Ceased
- 2002-05-21 IL IL15886202A patent/IL158862A0/xx unknown
- 2002-05-21 AR ARP020101877A patent/AR033903A1/es not_active Application Discontinuation
- 2002-05-21 EA EA200301222A patent/EA007408B1/ru not_active IP Right Cessation
- 2002-05-21 BR BR0209896-2A patent/BR0209896A/pt not_active Application Discontinuation
- 2002-05-21 HR HR20030949A patent/HRP20030949A2/xx not_active Application Discontinuation
- 2002-05-21 NZ NZ529572A patent/NZ529572A/en unknown
- 2002-05-21 TR TR2004/00295T patent/TR200400295T2/xx unknown
- 2002-05-21 EP EP02731931A patent/EP1395294A4/en not_active Withdrawn
- 2002-05-21 HU HU0400442A patent/HUP0400442A2/hu unknown
- 2002-05-21 CN CNB028103556A patent/CN1314445C/zh not_active Expired - Fee Related
- 2002-05-21 AU AU2002303869A patent/AU2002303869B2/en not_active Ceased
- 2002-05-21 YU YU98503A patent/YU98503A/sh unknown
- 2002-05-21 MY MYPI20021867A patent/MY137181A/en unknown
-
2003
- 2003-04-01 US US10/405,190 patent/US6890518B2/en not_active Expired - Fee Related
- 2003-07-08 TN TNPCT/US2002/016464A patent/TNSN03116A1/en unknown
- 2003-11-13 IL IL158862A patent/IL158862A/en not_active IP Right Cessation
- 2003-11-19 IS IS7043A patent/IS7043A/is unknown
- 2003-11-20 EC EC2003004855A patent/ECSP034855A/es unknown
- 2003-11-20 NO NO20035157A patent/NO20035157D0/no unknown
- 2003-11-20 CO CO03102566A patent/CO5540371A2/es unknown
- 2003-11-21 LV LVP-03-131A patent/LV13197B/en unknown
- 2003-11-21 MA MA27413A patent/MA26185A1/fr unknown
- 2003-12-17 LT LT2003107A patent/LT5153B/lt not_active IP Right Cessation
- 2003-12-22 BG BG108494A patent/BG108494A/xx unknown
-
2004
- 2004-11-02 US US10/980,652 patent/US20050152848A1/en not_active Abandoned
- 2004-11-21 ZA ZA200309085A patent/ZA200309085B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20030949A2 (en) | Pulmonary administration of chemically modified insulin | |
| TWI315201B (en) | Acidic insulin preparations having improved stability | |
| EP1438086A4 (en) | NOSE NEEDLE | |
| EP1386930A4 (en) | EXENDINDERIVATE | |
| HUP0302845A3 (en) | 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical | |
| EP1459776A4 (en) | SYRINGE | |
| IL157580A0 (en) | Inhalation drug combination | |
| MXPA03005980A (es) | Composiciones para administracion nasal de insulina. | |
| PL367639A1 (pl) | Nowy związek heterocykliczny i jego zastosowanie w medycynie | |
| AU2002308889A1 (en) | Novel heterocyclic compound and medicinal use thereof | |
| EP1416988A4 (en) | SYRINGE FOR SINGLE USE | |
| GB0128651D0 (en) | Syringe | |
| TW492328U (en) | Improved structure of syringe | |
| TW573751U (en) | Structure capable of preventing jaming | |
| TW533809U (en) | Structure of mattress set | |
| GB0108923D0 (en) | Administration of beneficial substances | |
| AU2002245598A1 (en) | Administration of sleep restorative agents | |
| CA93370S (en) | Inhaler | |
| CA93371S (en) | Inhaler | |
| AU2002360881A1 (en) | Anesthesia syringe | |
| GB0101470D0 (en) | Medicament | |
| GB0108590D0 (en) | Medicament | |
| SI1372624T1 (sl) | Zdravilo na osnovi tramadola | |
| GB0126910D0 (en) | Single use syringe | |
| TW499954U (en) | Improved structure of sphygmomanometer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |